Benedict Roylance

Every interaction refined, every need anticipated and every expectation exceeded.

For those who prioritise public health, MNS is the brand of equitable medicine access that delivers seamless, universal healthcare solutions anytime, anywhere, for everyone. At MNS our mission is to reduce health inequalities globally by guaranteeing access to life-saving medication irrespective of location race or gender. We achieve this through our innovative microneedle technology that enables painless, thermally stable and self-administered delivery of almost any therapeutic.

At Neobe Therapeutics we are engineering tumour-colonizing bacteria that will disrupt tumour micro environment barriers and enable immunotherapies in patients with immune-excluded tumours. Only around 20% of patients with solid tumors are estimated to currently benefit from immunotherapies. Multiple factors contribute to this low level of efficacy. Chief among them is the existence of an immunosuppressive microenvironment that leads to the generation of immune "cold" tumours. At Neobe we are harnessing the synthetic biology toolkit to engineer tumour-colonizing bacteria that locally disrupt this microenvironment. By acting locally within the tumor, these products avoid systemic toxicities while increasing drug efficacy. Disrupting these barriers and increasing immune cell infiltration in "cold" tumours will enable the success of immunotherapies in current non-responders.

ImmuONE specialises in human alveolar macrophage responses, epithelial cell culture platforms and testing services. Our respiratory tissue models closely resemble lung physiology to provide relevant, reliable, and reproducible results.   ImmuONE is partnered with the industry and academia to develop sustainable technologies for the future to support human-relevant, mechanistic driven safety assessments and develop animal product-free cell models.   We offer a range of standard and bespoke assessments for inhalation safety assessment needs. ImmuONE provides innovative solutions for inhalation toxicology, irritation sensitization, alveolar clearance, inflammation and can tailor to your inhalation safety assessment needs.    We invite you to learn more about how our products and services can help your business by visiting our website: www.immuone.com   Follow us on Twitter: @ImmuONE

The future of fertility care is here. Affordable, at-home ICI-based fertility treatment designed to help you get you pregnant.

Best in class BFR exercise equipment, made simple. Portable, gold standard BFR equipment built for professionals.

Kinomica is a pioneering precision medicine research and diagnostics company specialising in cell signalling with an interdisciplinary phosphoproteomics platform that combines LC–MS/MS with advanced proprietary bioinformatics to provide bespoke R&D and diagnostic services.

NuVision® is a tissue therapies company that provides amniotic membrane solutions to patients with ocular conditions. Our team work with Ophthalmologists, Optometrists, Contact Lens Opticians and Specialist nurses to provide our groundbreaking treatments to patients in a primary and secondary care setting. NuVision is a spin-out from the University of Nottingham.

Selentus develops innovative haemostatic technologies for better surgical outcomes. Selentus is developing a pipeline of products based on its unique technology platform that offer high performance, low cost manufacture and avoid the use of blood-derived materials. Selentus lead product, TenaTac®, was approved for sale in Europe in September 2019.

Transdermal Diagnostics, a MedTech venture spin-out from the University of Bath, is pioneering the development of bio-wearables with a primary focus on enhancing the prevention, diagnosis, and management of chronic conditions. Our revolutionary technology enables non-invasive, continuous co-monitoring of health biomarkers to catalyze a transformative shift in patient care and elevate overall quality of life. Presently, we are in the process of creating the worlds first 100% needle-free (and pain-free) CGM. This innovative device is designed to empower individuals living with diabetes, pre-diabetes, and obesity by providing them with personalized biological insights and enabling them to make informed decisions for a healthier lifestyle.

Every interaction refined, every need anticipated and every expectation exceeded.

Now part of the Grant Instruments Group. With over four decades of engineering expertise, Eltek delivers targeted and innovative monitoring and data-logging solutions across diverse industries. Our highly skilled engineering team, supported by a global network of specialist distributors, provides end-to-end support—from design and deployment through to ongoing maintenance and service. Committed to cost-efficiency and reliability, Eltek ensures scalable, robust systems tailored to your unique data logging and monitoring requirements. Highlights: • Over four decades of expertise in data logging and telemetry. • UK-based design and manufacturing with full in-house engineering. • Proven track record in sectors including pharmaceuticals, heritage & conservation, transportation, warehousing, and industrial monitoring. • Scalable systems designed to evolve with customer requirements. • Personal and responsive customer support from our dedicated team. Capabilities: • Data Logging Solutions: Portable, wireless, and modular systems tailored to each project. • Radio Telemetry: Reliable transmission of environmental data across complex or hard-to-reach sites. • Software Integration: User-friendly platforms for data acquisition, analysis, and reporting. • Custom Engineering: Bespoke design and consultancy for unique monitoring challenges. • Lifecycle Support: Guidance, calibration, and service throughout the lifetime of your system.

For those who prioritise public health, MNS is the brand of equitable medicine access that delivers seamless, universal healthcare solutions anytime, anywhere, for everyone. At MNS our mission is to reduce health inequalities globally by guaranteeing access to life-saving medication irrespective of location race or gender. We achieve this through our innovative microneedle technology that enables painless, thermally stable and self-administered delivery of almost any therapeutic.

At Neobe Therapeutics we are engineering tumour-colonizing bacteria that will disrupt tumour micro environment barriers and enable immunotherapies in patients with immune-excluded tumours. Only around 20% of patients with solid tumors are estimated to currently benefit from immunotherapies. Multiple factors contribute to this low level of efficacy. Chief among them is the existence of an immunosuppressive microenvironment that leads to the generation of immune "cold" tumours. At Neobe we are harnessing the synthetic biology toolkit to engineer tumour-colonizing bacteria that locally disrupt this microenvironment. By acting locally within the tumor, these products avoid systemic toxicities while increasing drug efficacy. Disrupting these barriers and increasing immune cell infiltration in "cold" tumours will enable the success of immunotherapies in current non-responders.

ImmuONE specialises in human alveolar macrophage responses, epithelial cell culture platforms and testing services. Our respiratory tissue models closely resemble lung physiology to provide relevant, reliable, and reproducible results.   ImmuONE is partnered with the industry and academia to develop sustainable technologies for the future to support human-relevant, mechanistic driven safety assessments and develop animal product-free cell models.   We offer a range of standard and bespoke assessments for inhalation safety assessment needs. ImmuONE provides innovative solutions for inhalation toxicology, irritation sensitization, alveolar clearance, inflammation and can tailor to your inhalation safety assessment needs.    We invite you to learn more about how our products and services can help your business by visiting our website: www.immuone.com   Follow us on Twitter: @ImmuONE